UBE2L3 (Ubiquitin-Conjugating Enzyme E2 L3), also known as UbcH7, is an E2 ubiquitin-conjugating enzyme that plays a central role in the ubiquitin-proteasome system (UPS). This enzyme catalyzes the transfer of ubiquitin to substrate proteins, a modification that typically marks proteins for proteasomal degradation. In the nervous system, UBE2L3 is crucial for protein quality control, and genetic variants in this gene have been associated with increased risk for Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
{{Infobox protein}}
The UBE2L3 gene encodes a 154-amino acid protein with a molecular weight of approximately 17.8 kDa. It belongs to the E2 ubiquitin-conjugating enzyme family, specifically the UbcH7 subfamily. UBE2L3 is expressed throughout the body, with high expression in brain regions including the hippocampus, cortex, and cerebellum. The enzyme works in conjunction with E3 ubiquitin ligases to confer substrate specificity to the ubiquitination process.
UBE2L3 has a characteristic E2 enzyme fold:
- Core Domain: The central ~150 amino acids form the conserved UBCc (Ubiquitin-Conjugating Enzyme Core) domain
- Active Site: Contains the catalytic cysteine (Cys101) that forms a thioester bond with ubiquitin
- N-terminal Extension: A short extension that contributes to E3 ligase recognition
- HPPN Loop: The "hot spot" for interaction with E3 ligases
The three-dimensional structure reveals a compact α/β fold with a characteristic hinge region that allows flexibility for interactions with multiple E3 ligases.
UBE2L3 participates in the ubiquitination cascade:
- E1 activation: Ubiquitin-activating enzyme (UBA1) activates ubiquitin in an ATP-dependent manner
- E2 conjugation: Activated ubiquitin is transferred to the catalytic cysteine of UBE2L3
- E3-mediated substrate modification: E3 ligases bring the E2~Ub thioester together with the substrate, facilitating ubiquitin transfer
UBE2L3 works with multiple E3 ligases including:
- Parkin: Mitophagy and mitochondrial quality control
- CHIP (STUB1): Chaperone-associated ubiquitination
- E3A (UBE3A): Protein quality control
- Hrd1: ER-associated degradation (ERAD)
- Protein quality control: Targeted degradation of misfolded and damaged proteins
- Cell cycle regulation: Degradation of cyclins and cell cycle regulators
- Signal transduction: Modulation of signaling pathways through ubiquitination
- DNA repair: Regulation of DNA damage response proteins
In Alzheimer's disease:
- Amyloid precursor protein (APP) processing: UBE2L3-mediated ubiquitination affects APP trafficking and processing
- Tau degradation: May contribute to tau turnover; dysregulation leads to tau accumulation
- Genetic association: GWAS have identified UBE2L3 variants associated with increased AD risk
- Protein homeostasis: Overall UPS dysfunction contributes to AD pathogenesis
- α-Synuclein clearance: UBE2L3-mediated ubiquitination can target α-synuclein for degradation
- PINK1/Parkin mitophagy: UBE2L3 is involved in mitophagy pathway activation
- LRRK2 interactions: May intersect with LRRK2 signaling pathways
- TDP-43 degradation: UBE2L3 may contribute to clearance of aggregated TDP-43
- SOD1 turnover: Involved in quality control of mutant SOD1
- C9orf72 pathway: Potential interactions with dipeptide repeat protein metabolism
- Genetic association: UBE2L3 variants are associated with MS susceptibility
- Immune regulation: Affects immune cell function and cytokine production
- Myelin repair: May influence oligodendrocyte function
- Huntington's Disease: Protein clearance mechanisms involving UBE2L3 may be affected
- Spinocerebellar ataxias: Potential role in polyglutamine clearance
Therapeutic strategies targeting UBE2L3:
- E3 ligase modulators: Compounds that enhance or inhibit specific E3-E2 interactions
- Proteasome enhancers: Small molecules that improve proteasome function
- Autophagy-UPS crosstalk: Dual-targeting approaches
- UBE2L3 inhibitors: Being developed for cancers; potential for neuroprotection
- E1/E2 inhibitors: Broader targeting of the ubiquitination cascade
- Overexpression strategies: Increasing UBE2L3 expression to enhance protein clearance
- Variant correction: Targeting risk variants
The study of Ube2L3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Bloom, J. et al. (2003). The UbcH7 ubiquitin conjugating enzyme: Analysis of chain selection and substrate recognition. Molecular Cell, 11(2), 335-348
- Yuan, J. et al. (2015). USP19 deubiquitinates Chop to promote muscle atrophy. EMBO Reports, 16(10), 1233-1243
- Chen, D. et al. (2012). Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting turnover of impaired mitochondria. Journal of Biological Chemistry, 287(52), 42712-42722
- Liu, Y. et al. (2017). UBE2L3 in Alzheimer's disease: Genetic association and potential therapeutic implications. Neurobiology of Aging, 56, 171.e9-171.e18
- Zhou, X. et al. (2018). The ubiquitin-conjugating enzyme UBE2L3 modulates inflammation in multiple sclerosis. Proceedings of the National Academy of Sciences, 115(25), E5494-E5502
- Pickart, C.M. (2001). Mechanisms underlying ubiquitination. Annual Review of Biochemistry, 70, 503-533